Mindful of debate on the current measures for RA activity, we conducted a prospective cohort study to determine whether levels of sCD14, a co-receptor for detection of lipopolysaccharide [12], represents RA activity and treatment responses to DMARDs when measured rapidly using the FRENDTM-CD14 system. Here, CD14 is linked to rheumatoid arthritis.